Gabriel L Sica

Summary

Affiliation: Emory University
Country: USA

Publications

  1. doi request reprint Lung cancer staging: pathology issues
    Gabriel L Sica
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA
    Semin Diagn Pathol 29:116-26. 2012
  2. pmc Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
    Bingshe Han
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Cancer Cell 27:852-63. 2015
  3. pmc Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer
    Rui Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America
    PLoS ONE 8:e74670. 2013
  4. pmc A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia Winship Cancer Institute of Emory University, Atlanta, Georgia
    Clin Cancer Res 21:1859-68. 2015
  5. pmc Novel small-molecule inhibitors of Bcl-XL to treat lung cancer
    Dongkyoo Park
    Departments of Radiation Oncology, Hematology and Medical Oncology, and Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    Cancer Res 73:5485-96. 2013
  6. doi request reprint Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
  7. pmc Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute of Emory University, Atlanta, Georgia
    Cancer Med 3:1579-94. 2014
  8. pmc CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC
    Rathi N Pillai
    Department of Hematology and Oncology, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 19:1603-11. 2013

Collaborators

Detail Information

Publications8

  1. doi request reprint Lung cancer staging: pathology issues
    Gabriel L Sica
    Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia, USA
    Semin Diagn Pathol 29:116-26. 2012
    ....
  2. pmc Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
    Bingshe Han
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Cancer Cell 27:852-63. 2015
    ..Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo. Development of this Bcl2-BH4 antagonist may provide a strategy to improve lung cancer outcome...
  3. pmc Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer
    Rui Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America
    PLoS ONE 8:e74670. 2013
    ..Based on our findings, treatment with erlotinib combined with niclosamide may offer an effective therapeutic approach to improve the prognosis of head and neck cancer. ..
  4. pmc A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia Winship Cancer Institute of Emory University, Atlanta, Georgia
    Clin Cancer Res 21:1859-68. 2015
    ..We studied the pharmacodynamic effects of everolimus in resectable non-small cell lung cancer (NSCLC) to inform further development of these agents in lung cancer...
  5. pmc Novel small-molecule inhibitors of Bcl-XL to treat lung cancer
    Dongkyoo Park
    Departments of Radiation Oncology, Hematology and Medical Oncology, and Pathology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
    Cancer Res 73:5485-96. 2013
    ..BXI-72 overcomes acquired radioresistance of lung cancer. On the basis of our findings, the development of BXI(s) as a new class of anticancer agents is warranted and represents a novel strategy for improving lung cancer outcome...
  6. doi request reprint Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
    ..Lung cancer is the leading cause of cancer-related mortality. Understanding patient attributes that enhance survival and predict recurrence is necessary to individualize treatment options...
  7. pmc Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute of Emory University, Atlanta, Georgia
    Cancer Med 3:1579-94. 2014
    ..Veliparib potentiates standard cytotoxic agents against SCLC in a cell-specific manner. This potentiation correlates with platinum sensitivity, DNA-PKcs expression and a 5-gene expression profile...
  8. pmc CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC
    Rathi N Pillai
    Department of Hematology and Oncology, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 19:1603-11. 2013
    ....